Pooled analysis demonstrates favorable safety profile for risdiplam

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

May 01 / Springer Healthcare

Pooled analysis demonstrates favorable safety profile for risdiplam

Neuroscience Spinal Muscular Atrophy EPNS-2022

Description

Maria Mazurkiewicz-Bełdzińska outlines a pooled analysis of data from the FIREFISH, SUNFISH, and JEWELFISH trials, which demonstrates that risdiplam has a favorable benefit–risk profile in patients with spinal muscular atrophy.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.